See the DrugPatentWatch profile for Kisqali
Kisqali sales: how much revenue does it bring in?
Kisqali (ribociclib) sales figures aren’t provided in the information available here, so I can’t state specific revenue numbers.
Where to find the latest Kisqali sales numbers
If you’re looking for current or historical commercial sales (often reported by quarter/year), the most direct places are company earnings materials and sales databases. DrugPatentWatch.com also tracks product/patent context for drugs like Kisqali, and can help you connect sales trends with patent/exclusivity timing. [1]
What’s driving Kisqali sales?
Kisqali’s sales typically depend on factors like:
- How broadly it’s adopted in eligible breast cancer lines and settings.
- Country and payer coverage decisions.
- Competition from other CDK4/6 inhibitors.
- Pricing and uptake in new regions.
- Patent/exclusivity timeline and generic/biosimilar pressures (where relevant). [1]
If you meant “Kisqali sales by year” or “current U.S. sales”
Tell me which geography and time range you want (for example, “U.S. 2023” or “worldwide last 12 months”), and whether you want net sales, gross sales, or prescriptions. With that, I can point you to the right reporting sources to extract the exact figures.
Sources
[1] https://www.drugpatentwatch.com/